Our company develops pre-symptom molecular biomarker testing technology for the early detection and prevention of various cancers and pre-cancers. Our testing technology and platform is objective, highly sensitive and specific, easy-to-use, low cost and non-invasive.
Our company screened human genome and identified novel class of DNA-based biomarkers for various cancers. Our company develops specific quantitation PCR-based assay using biomarkers as a panel, namely the “Cancer Clear™” molecular test.
Data from the Cancer Clear™ tests yield between 78% to 95% sensitivity and 82% to 96% specificity in distinguishing cancer versus normal control tissues.
Our molecular biomarker testing technology is able to detect cancer during the pre-cancerous state or pre-malignant state. Depending on the type of pre-cancer, early detection of pre-cancer will greatly increase the effectiveness of treatment and increase survival rate by more than 30% to 50%.